Research programme: antiviral therapeutics - H&P Labs

Drug Profile

Research programme: antiviral therapeutics - H&P Labs

Alternative Names: DEF-201; EboV inhibitors - H&P Labs

Latest Information Update: 24 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Brigham and Women's Hospital; Defyrus; Harvard University
  • Developer Brigham and Women's Hospital; Defyrus; H&P Labs; Harvard University
  • Class Adamantanes; Benzyl compounds; Interferons; Small molecules
  • Mechanism of Action Interferon alpha stimulants; Viral envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Viral infections
  • Research Ebola virus infections

Most Recent Events

  • 11 May 2015 H&P Labs secures $US350 000 from the National Research Council of Canada Industrial Research Assistance Program to finance development of antivirals
  • 08 Jan 2015 H&P Labs in-licenses Ebola virus inhibitors from Harvard University and Brigham and Women's Hospital
  • 08 Jan 2015 Early research in Ebola virus infections in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top